Amneal Ramps Up Progesterone Production Amid Surging US Menopause Treatment Demand
AMRX has more than doubled off its 52-week low of $7.665.
Summary
US progesterone supplies are tightening due to a sharp increase in demand for menopause treatment, following a late 2025 FDA label change. Amneal Pharmaceuticals, a key manufacturer, is actively increasing its manufacturing capacity at its New York facility to meet this surging demand. This market shift presents a significant opportunity for Amneal to expand its revenue and market share in a growing therapeutic area. CVS Health, among other pharmacies, is also experiencing supply challenges from manufacturers.
At the time of this announcement, AMRX was trading at $16.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2B. The 52-week trading range was $7.67 to $16.61. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.